Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.

Journal of the Chinese Medical Association : JCMA - 1 Sept 2013

Song Zhengbo, Lin Baochai, Shao Lan, Zhang Yiping

Abstract excerpt

BACKGROUND: Adenosquamous carcinoma (ASC) of the lung is a rare subtype of nonsmall-cell lung cancer (NSCLC). To date, the efficacious targeted therapy for advanced ASC remains unclear and the epidermal growth factor receptor (EGFR) mutation rate is not well known. METHODS: We retrospectively reviewed clinical information of patients with ASC who were treated with gefitinib or erlotinib at Zhejiang Cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Adenosquamous

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Quinazolines

Source

Identifiers

PMID: 23769878
DOI: 10.1016/j.jcma.2013.05.007

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.PMID 23769878Read ↗

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.Semantic proximity Read ↗

[Clinicopathologic Features and Prognostic Implications in 72 Cases with Lung Adenosquamous Carcinoma].Semantic proximity Read ↗

A case report of a dramatic response to Afatinib in a patient with advanced adenosquamous carcinoma lung cancer (ASC) harboring EGFR L861RSemantic proximity Read ↗

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.Semantic proximity Read ↗

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.Semantic proximity Read ↗

Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.Semantic proximity Read ↗

Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.Semantic proximity Read ↗

Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.Semantic proximity Read ↗

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lungSemantic proximity Read ↗

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.Semantic proximity Read ↗

[Erlotinib plus Bevacizumab Therapy for Postoperative Recurrence of Adenosquamous Cell Carcinoma Harboring EGFR Mutation-A Case Report].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.